Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Re-Opens Bank Account: Firm Again A Creditor After Genentech Sale

Executive Summary

Roche is once again a net creditor following its most recent offering of Genentech shares, CFO Henri Meier told the company's annual earnings conference March 30 in Basel, Switzerland.

You may also be interested in...



Biotech Licensing Often More Cost-Effective Than In-House R&D For Pharma

Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said

Biotech Licensing Often More Cost-Effective Than In-House R&D For Pharma

Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said

Avastin Launch Unlikely To Affect Xeloda Sales, Roche Says

Early launch data from Genentech's Avastin indicate the oncologic will not affect Xeloda sales, Roche Worldwide Pharmaceuticals Head William Burns said

Related Content

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel